ARC101 is being studied in a first-in-human Phase 1 trial for individuals with advanced solid tumors. The study aims to characterize safety and tolerability, describe pharmacokinetics, and assess preliminary antitumor activity in this heterogeneous patient population.
The trial has an estimated enrollment of 70 participants and is categorized as an interventional treatment study conducted in the oncology domain. The primary objective is to evaluate safety and tolerability, with pharmacokinetic profiling included to inform dosing considerations in this early-stage setting.
Preliminary signals of antitumor activity are to be explored, though data on efficacy are not yet established at this phase. The study design is single-arm and focus is on upfront safety and PK parameters in adults with advanced cancers that have progressed despite standard therapies or lack satisfactory alternatives.
Enrollment is ongoing with estimated completion anticipated in August 2028. Because this is a first-in-human study, explicit efficacy outcomes and long-term safety data are not yet available in the provided information.
If needed, confirm inclusion criteria, specific solid tumor types, dosing cohorts, and planned PK analyses from the trial registry.
ClinicalTrials.gov published a clinical update in Oncology on 03 Apr 2026.
The item focuses on ARC101 in Advanced Solid Tumors.
Review the original article for the full source wording and details.